ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Novartis, Bracco and Sichuan Biokin Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Novartis×Bracco×Sichuan Biokin Pharmaceutical×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

NovartisBraccoSichuan Biokin Pharmaceutical
studies on the registry3,90266146
open to participants now2125100
phase 3 studies under way94136
reach primary completion within a year128050
programswith a study of their own in two years77+7 named only319

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseNovartisBraccoSichuan Biokin Pharmaceutical
Phase 1

Novartis: 16 of its 77 programs at phase 1

  1. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  2. HJB647phase 1
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1
  5. Actinium Ac 225-ETN029phase 1

and 11 more — sign in to see them all

21%
00%

Sichuan Biokin Pharmaceutical: 8 of its 19 programs at phase 1

  1. SI-B036phase 1
  2. BL-M24D1phase 1
  3. GNC-077phase 1
  4. Antibody-drug Conjugate BL-M17D1phase 1
  5. BL-ARC002phase 1

and 3 more — sign in to see them all

42%
Phase 2

Novartis: 35 of its 77 programs at phase 2

  1. Lutetium-177phase 2
  2. rapcabtagene autoleucelphase 2
  3. DDY391phase 2
  4. arumakimigphase 2
  5. QCZ484phase 2

and 30 more — sign in to see them all

45%

Bracco: 2 of its 3 programs at phase 2

  1. Fluorine F 18 FPyQCPphase 2
  2. Gallium-68phase 2
67%

Sichuan Biokin Pharmaceutical: 4 of its 19 programs at phase 2

  1. BL-M08D1phase 2
  2. emfizatamabphase 2
  3. BL-M09D1phase 2
  4. glecirasibphase 2
21%
Phase 3

Novartis: 18 of its 77 programs at phase 3

  1. remibrutinibphase 3
  2. ianalumabphase 3
  3. iptacopanphase 3
  4. pelabresibphase 3
  5. pelacarsenphase 3

and 13 more — sign in to see them all

23%
00%

Sichuan Biokin Pharmaceutical: 7 of its 19 programs at phase 3

  1. izalontamab brengitecanphase 3
  2. trastuzumab brengitecanphase 3
  3. Anti-CD33 Antibody-drug Conjugate BL-M11D1phase 3
  4. Anti-DLL3 Antibody-drug Conjugate BL-M14D1phase 3
  5. Cytarabinephase 3

and 2 more — sign in to see them all

37%
Approved, new studies

Novartis: 8 of its 77 programs at approved, new studies

  1. inclisiranapproved, new study
  2. Alpelisibapproved, new study
  3. asciminibapproved, new study
  4. secukinumabapproved, new study
  5. ruxolitinibapproved, new study

and 3 more — sign in to see them all

10%

Bracco: 1 of its 3 programs at approved, new studies

  1. fluciclovine F-18approved, new study
33%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Novartis27 readouts · 5 phase 3

Novartis, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. inclisiranapproved, new study · Nov 27 · NCT06501443

Novartis, Dec ’26: 5 programs whose next study reaches primary completion

  1. luxdegalutamidephase 2 · Dec 3 · NCT06991556
  2. HJB647phase 1 · Dec 8 · NCT07465653
  3. gallium 68 PSMA-11phase 2 · Dec 23 · NCT05849298
  4. iptacopanphase 3 · Dec 30 · NCT06388941
  5. Lutetium-177phase 2 · Dec 30 · NCT05870579

Novartis, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. opnurasibphase 3 · Jan 25 · NCT04699188
  2. Alpelisibapproved, new study · Jan 28 · NCT05038735

Novartis, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. cipargaminphase 2 · Feb 4 · NCT07811908
  2. ganaplacidephase 3 · Feb 4 · NCT07811908
  3. remibrutinibphase 3 · Feb 22 · NCT06868212

Novartis, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PKN605phase 2 · Mar 1 · NCT07797322
  2. EDI-048phase 2 · Mar 23 · NCT07249463
  3. ianalumabphase 3 · Mar 26 · NCT05639114

Novartis, Apr ’27: 4 programs whose next study reaches primary completion

  1. arumakimigphase 2 · Apr 22 · NCT07203001
  2. DII235phase 2 · Apr 26 · NCT07235046
  3. QCZ484phase 2 · Apr 28 · NCT07610278
  4. delpacibart zotadirsenphase 3 · Apr 30 · NCT06244082

Novartis, May ’27: 3 programs whose next study reaches primary completion

  1. GIA632phase 2 · May 17 · NCT07220577
  2. luxdegalutamidephase 2 · May 25 · NCT05067140
  3. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1 · May 31 · NCT05397496
·

Novartis, Jul ’27: 3 programs whose next study reaches primary completion

  1. EYU688phase 2 · Jul 22 · NCT06006559
  2. LXE408phase 2 · Jul 22 · NCT06632600
  3. GXV-813phase 2 · Jul 29 · NCT07467993

Novartis, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zigakibartphase 3 · Aug 10 · NCT05852938
  2. YMI024phase 2 · Aug 15 · NCT07830719

Novartis, Sep ’27: 1 program whose next study reaches primary completion

  1. asciminibapproved, new study · Sep 3 · NCT04925479
·
Bracco0 readouts · 0 phase 3············
Sichuan Biokin Pharmaceutical8 readouts · 1 phase 3

Sichuan Biokin Pharmaceutical, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. izalontamab brengitecanphase 3 · Nov 0 · NCT06118333

Sichuan Biokin Pharmaceutical, Dec ’26: 4 programs whose next study reaches primary completion

  1. Anti-CD33 Antibody-drug Conjugate BL-M11D1phase 3 · Dec 0 · NCT05924750
  2. BL-M08D1phase 2 · Dec 0 · NCT06718621
  3. emfizatamabphase 2 · Dec 0 · NCT05623982
  4. trastuzumab brengitecanphase 3 · Dec 0 · NCT06114511
·

Sichuan Biokin Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion

  1. Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1phase 1 · Feb 28 · NCT07021066
··

Sichuan Biokin Pharmaceutical, May ’27: 1 program whose next study reaches primary completion

  1. BL-M09D1phase 2 · May 0 · NCT06954077

Sichuan Biokin Pharmaceutical, Jun ’27: 1 program whose next study reaches primary completion

  1. GNC-077phase 1 · Jun 0 · NCT06755242
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Novartis

New programs 5

  • pacibekitugphase 3 · first study · Nov 9 · Myocardial Infarction
  • DKB903phase 1 · first study · Nov 2 · Arthritis, Rheumatoid
  • TRB191phase 1 · first study · Oct 26 · Small Cell Lung Carcinoma
  • XEP527phase 1 · first study · Oct 26 · Schizophrenia
  • YMI024phase 2 · first study · Sep 15 · Coronary Artery Disease

Reached a new phase 1

Study stopped 6

  • remibrutinibphase 3 · terminated Nov 20“Sponsor decision based on pre-specified futility efficacy criteria being met.” · NCT06744920
  • Lutetium-177phase 1 · terminated Nov 17“Sponsor decision and not a consequence of any safety concerns.” · NCT06379217
  • pelacarsenphase 3 · terminated Nov 10“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT05900141
  • opnurasibphase 3 · terminated Nov 6“Business reasons and not based on any safety concerns.” · NCT05132075
  • ianalumabphase 2 · withdrawn Oct 15“The study was discontinued due to evolving scientific \& feasibility considerations that could adversely af…” · NCT07039422
  • pelacarsenphase 3 · withdrawn Oct 14“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT07625306

Primary completion later 6

Bracco

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Sichuan Biokin Pharmaceutical

New programs 2

  • SI-B037phase 1 · first study · Nov 10
  • glecirasibphase 2 · first study · Sep 14 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 21 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionNovartisBraccoSichuan Biokin Pharmaceutical
Prostatic Neoplasmsall three · compare here

Novartis in Prostatic Neoplasms: 13 programs

  1. Atrasentanphase 3
  2. actinium AC-225 vipivotide tetraxetanphase 3
  3. Gallium-68phase 3
  4. ARPIphase 3
  5. Lutetium-177phase 2

and 8 more — sign in to see them all

Their studies: Novartis’s studies of Prostatic Neoplasms in search

Bracco in Prostatic Neoplasms: 2 programs

  1. Gallium-68phase 2
  2. fluciclovine F-18approved, new study

Their studies: Bracco’s studies of Prostatic Neoplasms in search

Sichuan Biokin Pharmaceutical in Prostatic Neoplasms: 1 program

  1. Lutetium-177phase 1

Their studies: Sichuan Biokin Pharmaceutical’s studies of Prostatic Neoplasms in search

Breast Neoplasmsall three · compare here

Novartis in Breast Neoplasms: 6 programs

  1. Gallium-68phase 3
  2. Lutetium-177phase 2
  3. GVV858phase 2
  4. ERW316phase 2
  5. IEV407phase 1

and 1 more — sign in to see them all

Their studies: Novartis’s studies of Breast Neoplasms in search

Bracco in Breast Neoplasms: 1 program

  1. Gallium-68phase 2

Their studies: Bracco’s studies of Breast Neoplasms in search

Sichuan Biokin Pharmaceutical in Breast Neoplasms: 6 programs

  1. izalontamab brengitecanphase 3
  2. trastuzumab brengitecanphase 3
  3. SI-B036phase 1
  4. GNC-077phase 1
  5. Antibody-drug Conjugate BL-M17D1phase 1

and 1 more — sign in to see them all

Their studies: Sichuan Biokin Pharmaceutical’s studies of Breast Neoplasms in search

Colorectal Neoplasmsall three · compare here

Novartis in Colorectal Neoplasms: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Colorectal Neoplasms in search

Bracco in Colorectal Neoplasms: 2 programs

  1. Fluorine F 18 FPyQCPphase 2
  2. Gallium-68phase 2

Their studies: Bracco’s studies of Colorectal Neoplasms in search

Sichuan Biokin Pharmaceutical in Colorectal Neoplasms: 1 program

  1. trastuzumab brengitecanphase 3

Their studies: Sichuan Biokin Pharmaceutical’s studies of Colorectal Neoplasms in search

Urinary Bladder Neoplasmsall three · compare here

Novartis in Urinary Bladder Neoplasms: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Urinary Bladder Neoplasms in search

Bracco in Urinary Bladder Neoplasms: 1 program

  1. Gallium-68phase 2

Their studies: Bracco’s studies of Urinary Bladder Neoplasms in search

Sichuan Biokin Pharmaceutical in Urinary Bladder Neoplasms: 1 program

  1. trastuzumab brengitecanphase 3

Their studies: Sichuan Biokin Pharmaceutical’s studies of Urinary Bladder Neoplasms in search

Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

Novartis in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. opnurasibphase 3
  2. Lutetium-177phase 2
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1

Their studies: Novartis’s studies of Carcinoma, Non-Small-Cell Lung in search

–

Sichuan Biokin Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 9 programs

  1. izalontamab brengitecanphase 3
  2. trastuzumab brengitecanphase 3
  3. PD-1/VEGF Bispecific Antibodyphase 3
  4. BL-M09D1phase 2
  5. glecirasibphase 2

and 4 more — sign in to see them all

Their studies: Sichuan Biokin Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Small Cell Lung Carcinoma2 of 3 · compare here–

Sichuan Biokin Pharmaceutical in Small Cell Lung Carcinoma: 2 programs

  1. izalontamab brengitecanphase 3
  2. Anti-DLL3 Antibody-drug Conjugate BL-M14D1phase 3

Their studies: Sichuan Biokin Pharmaceutical’s studies of Small Cell Lung Carcinoma in search

Arthritis, Rheumatoid2 of 3 · compare here–

Sichuan Biokin Pharmaceutical in Arthritis, Rheumatoid: 1 program

  1. emfizatamabphase 2

Their studies: Sichuan Biokin Pharmaceutical’s studies of Arthritis, Rheumatoid in search

Lupus Erythematosus, Systemic2 of 3 · compare here–

Sichuan Biokin Pharmaceutical in Lupus Erythematosus, Systemic: 1 program

  1. emfizatamabphase 2

Their studies: Sichuan Biokin Pharmaceutical’s studies of Lupus Erythematosus, Systemic in search

Lymphoma, Large B-Cell, Diffuse2 of 3 · compare here

Novartis in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. blinatumomabphase 2

Their studies: Novartis’s studies of Lymphoma, Large B-Cell, Diffuse in search

–

Sichuan Biokin Pharmaceutical in Lymphoma, Large B-Cell, Diffuse: 2 programs

  1. BL-M08D1phase 2
  2. emfizatamabphase 2

Their studies: Sichuan Biokin Pharmaceutical’s studies of Lymphoma, Large B-Cell, Diffuse in search

Multiple Myeloma2 of 3 · compare here

Novartis in Multiple Myeloma: 2 programs

  1. pelabresibphase 3
  2. zigakibartphase 3

Their studies: Novartis’s studies of Multiple Myeloma in search

–

Sichuan Biokin Pharmaceutical in Multiple Myeloma: 1 program

  1. BL-M24D1phase 1

Their studies: Sichuan Biokin Pharmaceutical’s studies of Multiple Myeloma in search

Squamous Cell Carcinoma of Head and Neck2 of 3 · compare here

Novartis in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. Alpelisibapproved, new study

Their studies: Novartis’s studies of Squamous Cell Carcinoma of Head and Neck in search

–

Sichuan Biokin Pharmaceutical in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. BL-M08D1phase 2
  2. BL-M24D1phase 1

Their studies: Sichuan Biokin Pharmaceutical’s studies of Squamous Cell Carcinoma of Head and Neck in search

Carcinoma, Neuroendocrine2 of 3 · compare here

Novartis in Carcinoma, Neuroendocrine: 1 program

  1. Autologous Anti-DLL3 CAR-T Cells DJI136phase 2

Their studies: Novartis’s studies of Carcinoma, Neuroendocrine in search

–

Sichuan Biokin Pharmaceutical in Carcinoma, Neuroendocrine: 1 program

  1. Anti-DLL3 Antibody-drug Conjugate BL-M14D1phase 3

Their studies: Sichuan Biokin Pharmaceutical’s studies of Carcinoma, Neuroendocrine in search

Show all 21

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Novartis 56 of 77 · Bracco 2 of 3 · Sichuan Biokin Pharmaceutical 9 of 19 programs (19 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Novartis: 7).